Eaton Vance Management Cellectis S.A. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
32Shares Held
9.73MCall Options Held
0Put Options Held
30.9K-
Long Focus Capital Management, LLC San Juan, PR4.49MShares$9.92 Million0.64% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$4.09 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$3.18 Million0.0% of portfolio
-
Baillie Gifford & CO708KShares$1.56 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA437KShares$965,7700.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $101M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...